141 related articles for article (PubMed ID: 7936633)
1. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis.
Marin MC; Hsu B; Meyn RE; Donehower LA; el-Naggar AK; McDonnell TJ
Oncogene; 1994 Nov; 9(11):3107-12. PubMed ID: 7936633
[TBL] [Abstract][Full Text] [Related]
2. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.
Marin MC; Hsu B; Stephens LC; Brisbay S; McDonnell TJ
Exp Cell Res; 1995 Apr; 217(2):240-7. PubMed ID: 7698223
[TBL] [Abstract][Full Text] [Related]
3. Bax accelerates tumorigenesis in p53-deficient mice.
Knudson CM; Johnson GM; Lin Y; Korsmeyer SJ
Cancer Res; 2001 Jan; 61(2):659-65. PubMed ID: 11212265
[TBL] [Abstract][Full Text] [Related]
4. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool.
Luo JL; Yang Q; Tong WM; Hergenhahn M; Wang ZQ; Hollstein M
Oncogene; 2001 Jan; 20(3):320-8. PubMed ID: 11313961
[TBL] [Abstract][Full Text] [Related]
5. T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53.
Brady HJ; Salomons GS; Bobeldijk RC; Berns AJ
EMBO J; 1996 Mar; 15(6):1221-30. PubMed ID: 8635454
[TBL] [Abstract][Full Text] [Related]
6. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis.
Hsu B; Marin MC; el-Naggar AK; Stephens LC; Brisbay S; McDonnell TJ
Oncogene; 1995 Jul; 11(1):175-9. PubMed ID: 7624125
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cell death by lens-specific overexpression of bcl-2 in transgenic mice.
Fromm L; Overbeek PA
Dev Genet; 1997; 20(3):276-87. PubMed ID: 9216067
[TBL] [Abstract][Full Text] [Related]
8. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.
Burns TF; Bernhard EJ; El-Deiry WS
Oncogene; 2001 Aug; 20(34):4601-12. PubMed ID: 11498783
[TBL] [Abstract][Full Text] [Related]
9. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line.
Wang Y; Szekely L; Okan I; Klein G; Wiman KG
Oncogene; 1993 Dec; 8(12):3427-31. PubMed ID: 8247547
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita T; Krajewski S; Krajewska M; Wang HG; Lin HK; Liebermann DA; Hoffman B; Reed JC
Oncogene; 1994 Jun; 9(6):1799-805. PubMed ID: 8183579
[TBL] [Abstract][Full Text] [Related]
11. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
[TBL] [Abstract][Full Text] [Related]
14. The bcl-2 oncogene and apoptosis.
Hockenbery DM
Semin Immunol; 1992 Dec; 4(6):413-20. PubMed ID: 1286168
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability.
Luke JJ; Van De Wetering CI; Knudson CM
Cell Death Differ; 2003 Jun; 10(6):740-8. PubMed ID: 12761582
[TBL] [Abstract][Full Text] [Related]
16. Bax suppresses tumorigenesis and stimulates apoptosis in vivo.
Yin C; Knudson CM; Korsmeyer SJ; Van Dyke T
Nature; 1997 Feb; 385(6617):637-40. PubMed ID: 9024662
[TBL] [Abstract][Full Text] [Related]
17. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
Kuo ML; Chou YW; Chau YP; Huang TS
Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II-induced p53-dependent cardiac apoptotic cell death: its prevention by metallothionein.
Liu Q; Wang G; Zhou G; Tan Y; Wang X; Wei W; Liu L; Xue W; Feng W; Cai L
Toxicol Lett; 2009 Dec; 191(2-3):314-20. PubMed ID: 19808082
[TBL] [Abstract][Full Text] [Related]
19. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
20. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
